Sanofi adds €1bn funding for biomanufacturing projects in France
Betsy Goodfellow | May 13, 2024 | News story | Business Services | Biomanufacturing, Pharmacy, Sanofi, funding, investment
Sanofi has announced that it has made a new investment of at least €1bn for the creation of new bioproduction capacity at its sites in Vitry-sur-Seine (Val de Marne), Le Trait (Seine-Maritime) and Lyon Gerland (Rhône), all France.
The investment is intended to create over 500 new jobs, as well as improving France’s ability to ‘control the production of essential medicines from start to finish’, according to the press release.
This also brings Sanofi’s overall investment in major projects around the production of medicines and vaccines in France since the COVID-19 pandemic to more than €3.5bn.
At the Vitry-sur-Seine site, the company plans to invest €1bn to build a new facility, doubling the site’s monoclonal antibody production capacity. At the Le Trait site, €100m will be invested in developing a new capacity for biologics formulation, filling, device assembly and packaging, and lastly at Lyon Gerland, it will invest €10m to locate the production of TZield in France.
Paul Hudson, chief executive officer at Sanofi, commented: “Thanks to the transformation undertaken since 2020, Sanofi has a record number of medicines and vaccines in development that could become best-in-class and help meet major public health challenges. With these unprecedented industrial investments, we remain true to our history by once again choosing France to produce these future medicines and make them available to patients around the world. France is, and always will be, at the heart of Sanofi’s strategy.”
Betsy Goodfellow
Related Content
Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …
Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …
Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline
Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …
